CytoSolve® Supports British American Tobacco Government Filing via In Silico Systems Architecture for Relaxation Pathway and Harm Reduction Research Innovation

Partner Description

British American Tobacco
British American Tobacco (BAT) is a global organization with advanced research and development capabilities focused on biological mechanisms relevant to consumer products and harm-reduction science. BAT’s R&D programs emphasize scientific transparency, regulatory compliance, and evidence-based innovation through analytical, biological, and computational research methodologies.

Challenge

British American Tobacco required a rigorous, regulator-ready scientific framework to support government filings related to relaxation and stress-modulation research. The underlying biology spans highly interconnected molecular systems, including neurotransmitter signaling, hormonal regulation, immune-mediated inflammation, and neuromodulatory feedback loops.

Traditional experimental approaches alone are limited in their ability to efficiently characterize non-linear interactions, combination effects, and system-wide responses across multiple pathways. For government submission and regulatory review, BAT required a scalable, quantitative, and mechanistic methodology capable of evaluating individual ingredients and combinations with clear biological traceability and reduced dependence on extensive early-stage experimental studies.

How CytoSolve® Helped

CytoSolve® supported British American Tobacco’s government filing activities by delivering a structured, literature-grounded computational systems architecture.

Identified six core molecular pathway systems governing relaxation biology based on peer-reviewed literature:

  • Gut microbiome–neuroinflammation signaling.
  • Hypothalamic–pituitary–adrenal (HPA) axis signaling.
  • Brain-derived neurotrophic factor (BDNF) signaling.
  • GABA and serotonin neurotransmitter pathways.
  • Dopaminergic catecholamine signaling.
  • Endocannabinoid signaling centered on anandamide (AEA).
Independently translated each pathway into validated mathematical models using ordinary differential equations and encoded them in SBML format for regulatory transparency.

Dynamically integrated all six pathway models into a unified quantitative systems architecture while preserving individual pathway identities.

Conducted in silico simulations of six shortlisted bioactive ingredients across physiologically relevant dose ranges, evaluating effects on key biomarkers both individually and in combination..

Generated mechanistic evidence packages suitable for inclusion in government filings, supporting ingredient prioritization and formulation rationale.

Key Benefits Realized

  • Regulatory-Grade Systems Architecture – Mechanistic framework suitable for government filing and scientific review.
  • Systems-Level Quantification – Integrated assessment across interconnected relaxation pathways.
  • Mechanistic Traceability – Clear linkage between ingredient exposure and molecular outcomes.
  • Scalable In Silico Screening – Rapid evaluation of multiple ingredients and combinations.
  • Combination-Ready Framework – Computational foundation supporting formulation optimization.
  • Reduced Experimental Burden – Lower reliance on early-stage in vitro and in vivo studies.

Outcome

The CytoSolve® Systems Architecture enabled British American Tobacco to translate complex relaxation biology into a coherent, government-ready computational evidence framework. By integrating six molecular pathway systems into a single in silico architecture, CytoSolve® supported BAT’s regulatory submissions with quantitative, literature-grounded mechanistic insight. This case study demonstrates how CytoSolve® empowers science-driven organizations to meet government filing requirements through transparent, scalable, and systems-level computational biology aligned with modern regulatory and harm-reduction research standards